Does ONC pay a dividend?

The cached stock data on this page does not show a positive dividend yield for ONC. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does ONC stock do?

Commercial-stage global oncology biotechnology enterprise generating revenue through proprietary commercial blockbusters (BRUKINSA, TEVIMBRA) and strategic biopharma partnerships.

What is ONC stock's price target?

This cached page does not contain a precise model fair value for ONC.

The TradeMates model verdict for ONC is HOLD with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.

Is ONC a good dividend stock?

ONC is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

ONC (ONC) Stock Analysis

Q: Is ONC stock a good investment?

The cached TradeMates AI model rates ONC as HOLD with an investment score of 49/100. The AI model evaluates BeOne Medicines AG as a Hold. The company successfully executed a financial inflection in 2025, reaching $5.34B in revenue (55.7% 3-year CAGR) and positive net income of $286.9M. However, trailing P/S of 52.4x limits near-term multiple expansion. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

BRUKINSA commercial scaling drives 2025 profitability inflection ($287M net income), offset by elevated valuation multiples (PS 52x).

Investment score: 49/100

The AI model evaluates BeOne Medicines AG as a Hold. The company successfully executed a financial inflection in 2025, reaching $5.34B in revenue (55.7% 3-year CAGR) and positive net income of $286.9M. However, trailing P/S of 52.4x limits near-term multiple expansion.

View the full interactive analysis